Description: Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). The company was formerly known as Tourmaline Bio, LLC and changed its name to Tourmaline Bio, Inc. in September 2022. Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.
Home Page: www.tourmalinebio.com
27 West 24th Street
New York,
NY
10010
United States
Phone:
646 481 9832
Officers
| Name | Title |
|---|---|
| Dr. Sandeep C. Kulkarni M.D. | Co-Founder, CEO & Director |
| Dr. Kevin B. Johnson M.B.A., Ph.D. | Chief Regulatory Officer |
| Mr. Ryan Robinson CPA | CFO & Treasurer |
| Dr. Susan Dana Jones Ph.D. | Chief Technology Officer |
| Mr. W. Bradford Middlekauff J.D. | Chief Business Officer, General Counsel & Corporate Secretary |
| Ms. Kimberly Piorkowski | Vice President of People, Culture & Compliance |
| Ms. Dora Rau | Senior VP & Head of Quality |
| Mr. Gerhard Hagn Pharm.D. | Senior VP and Head of Commercial & Business Development |
| Dr. Emil M. deGoma M.D. | Senior Vice President of Medical Research |
| Dr. Kristine Erickson O.D., Ph.D. | VP & TA Head of Ophthalmology, Medical Research |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7986 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-05-07 |
| Fiscal Year End: | December |
| Full Time Employees: | 74 |